Income statement
EUR
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 221M | 175M | 158M | 196M | 230M |
| Gross Profit | 209M | 167M | 149M | 183M | 213M |
| Operating Income | 40M | 6M | -4M | 44M | 92M |
| EBITDA | 48M | 21M | 5M | 52M | 104M |
| Net Income | 75M | 26M | 1M | 49M | 93M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$79.49
+0.00% today
1Y Change
-14.13%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pharma Mar, S.A. (PHMMF) is a Healthcare stock with a market cap of $1.66B and listed on OTC. The stock last traded around $79.49 and down 14.1% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +26.6%, EPS growth of +192.6%, a dividend yield of 0.8%. What stands out right now is revenue +26.6%, EPS +192.6%, free cash flow +561.2% with operating margin 24.9% and ROIC 17.6%. The dividend is present but secondary, with a yield around 0.8%. Valuation sits in the middle of the pack at P/E 22.0 and price/sales 7.5. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines PHMMF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHMMF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHMMF Max Drawdown
-28.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHMMF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$229.8M
+17.1% YoY
FY Net Income
$92.9M
+88.1% YoY
Free Cash Flow
$17.9M
-39.3% YoY
Revenue Growth
+26.6%
EPS Growth
+192.6%
Gross Margin
92.6%
Net Margin
33.9%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 221M | 175M | 158M | 196M | 230M |
| Gross Profit | 209M | 167M | 149M | 183M | 213M |
| Operating Income | 40M | 6M | -4M | 44M | 92M |
| EBITDA | 48M | 21M | 5M | 52M | 104M |
| Net Income | 75M | 26M | 1M | 49M | 93M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 18M | 63M | 60M | 150M | 113M |
| Total Assets | 395M | 350M | 341M | 393M | 368M |
| Total Liabilities | 142M | 141M | 147M | 170M | 190M |
| Shareholder Equity | 252M | 208M | 193M | 223M | 178M |
| Total Debt | 51M | 51M | 44M | 43M | 49M |
| Net Debt | 33M | -12M | -16M | -107M | -64M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
26M
-33.0% YoY
Capital Expenditures
8M
+11.9% YoY
Free Cash Flow
18M
-39.3% YoY
Key ratios
Gross Margin
92.6%
Operating Margin
24.9%
Net Margin
33.9%
ROE
35.4%
Debt / Equity
0.20x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.